Why did FDA grant accelerated approval to Genglycos for GSDIa?

FDA granted accelerated approval to Genglycos because trial data showed a statistically significant 31% mean reduction in daily cornstarch intake versus placebo over 48 weeks in patients with glycogen storage disease type Ia. The approval is limited to use alongside nutritional management, and the manufacturer must complete confirmatory trials to verify clinical benefit.